Embecta opened lower at $6.51, compared with its previous close of $6.53. In the last trading session, the stock traded between $6.42 and $6.59. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Embecta is now worth
$ 21.07
Resulting in a loss of
$ 78.93 (78.93%)
Note: Past profits do not guarantee future returns.
Rating from 1 Analysts
Today's Change
$-0.10 (-1.59%)
Day High
$6.59
Day Low
$6.42
Day Open
$6.51
Prev Close
$6.53
Volume
8,28,679
1W Return
-1.06%
1M Return
7.37%
3M Return
31.55%
6M Return
91.25%
1Y Return
-54.81%
Market Cap ($ Mn)
364
PE Ratio
3.44
PB Ratio
-
PEG Ratio
0.18
ROE
-
ROCE
28.10%
EPS (TTM)
$0.37
1 Week
-1.06%
1 Month
7.37%
3 Months
31.55%
6 Months
91.25%
9 Months
-36.12%
Bernstein Liebhard investigates Embecta Corp for fiduciary breaches
Bernstein Liebhard LLP is investigating potential fiduciary duty breaches by Embecta Corp leadership. Investigation targets shareholders who purchased shares before November 25, 2025. Firm has recovered over $3.5 billion for clients since 1993. Contact Peter Allocco at (212) 951-2030 for confidential consultations.
1mo agoBernstein Liebhard probes Embecta for potential fiduciary duty breaches
Bernstein Liebhard LLP investigates potential fiduciary duty breaches by Embecta Corp. directors and officers. The firm assesses if leadership acted in shareholders' best interests using publicly available information. Shareholders who purchased EMBC stock before November 25, 2025 are urged to contact the firm. Bernstein Liebhard has recovered over $3.5 billion for clients since 1993.
2mo agoBernstein Liebhard probes Embecta fiduciary duty breaches
Bernstein Liebhard LLP joins multiple firms investigating Embecta Corp. for potential fiduciary duty breaches following a 57.8% stock plunge. The class action alleges misleading guidance regarding the insulin pen needle business led to a severe Q2FY26 miss and a 93% dividend cut. Shareholders who bought before November 25, 2025, are urged to contact counsel.
2mo agoEmbecta Corp investors face Aug 17 lead plaintiff deadline
Embecta Corp investors who bought shares between November 2025 and May 2026 must act by August 17, 2026, to serve as lead plaintiff in a securities class action. The lawsuit alleges the company misled investors about its financial health and pen needle business resilience, leading to a massive stock decline and guidance cuts.
3mo agoEmbecta Corp Q3 Results: Company Reports Fiscal 2026 Third Quarter Financials
Embecta Corp released its Q3 FY26 results on Aug 7, 2026, hosting an investor call to discuss performance. The company is pivoting from insulin delivery to broad medical supplies. Specific financial metrics were not included in the initial brief.
3mo agoEmbecta raises FY2026 EPS guidance to $1.80-$1.90
Embecta raises FY2026 adjusted EPS guidance to $1.80-$1.90, beating the $1.59 estimate, while affirming sales of $1.015B-$1.035B. The revision highlights margin strength despite stable revenue expectations.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Embecta is now worth
$ 21.07
Resulting in a loss of
$ 78.93 (78.93%)
Note: Past profits do not guarantee future returns.
